David Wright, MD
Medical Oncology · Tampa, FLNPI 1699745638
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Bristol Myers Squibb at 29.2% of the total. Reporting peaked in 2019 at $18,427 and has fallen 74.0% since, to $4,795 in 2025.
Across 1,129 payments — averaging $42.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$14K
- AstraZeneca$10K
- E.r. Squibb & Sons, L.L.C.$4K
- Novartis$2K
- Johnson & Johnson$1K
- Epizyme, Inc.$1K
- plus $15K from 54 others
Across 332 payments — averaging $9950.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$1.4M
- AstraZeneca$531K
- Bristol Myers Squibb$387K
- Pharmacyclics LLC, An Abbvie Company$289K
- E.r. Squibb & Sons, L.L.C.$203K
- Sanofi US Services Inc.$159K
- plus $305K from 9 others
What the payments were for
- Consulting fees$14,68931%
- Speaking & faculty fees$10,66322%
- Travel & lodging$120%
- Food & beverage$22,00546%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,485 in reported general payments places this provider in the 80th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 138 | $2,033,507 |
| JakafiRuxolitinib Phosphate | 36 | $616,414 |
| PomalystPomalidomide | 27 | $603,874 |
| ImbruvicaIbrutinib | 33 | $518,294 |
| IbrancePalbociclib | 33 | $511,757 |
| BrukinsaZanubrutinib | 31 | $435,345 |
| CalquenceAcalabrutinib Maleate | 32 | $392,777 |
| PromactaEltrombopag Olamine | 18 | $310,832 |
| XtandiEnzalutamide | 15 | $176,094 |
| KisqaliRibociclib Succinate | 12 | $163,460 |
| AlecensaAlectinib Hcl | 12 | $129,173 |
| VenclextaVenetoclax | 19 | $107,903 |
| EliquisApixaban | 105 | $74,314 |
| XareltoRivaroxaban | 44 | $35,053 |
| Abiraterone Acetate | 17 | $21,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $13,863 | $2,033,507138 claims |
| Incyte CorporationJakafi | $793 | $616,41436 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $3,584 | $603,87427 claims |
| PfizerIbrance, Eliquis | $1,183 | $586,071138 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $319 | $518,29433 claims |
| NovartisPromacta, Kisqali | $1,909 | $474,29230 claims |
| Beigene USA, Inc.Brukinsa | $194 | $435,34531 claims |
| AstraZenecaCalquence | $10,278 | $392,77732 claims |
| Astellas Pharma US IncXtandi | $260 | $176,09415 claims |
| Genentech USA, Inc.Alecensa | $492 | $129,17312 claims |
| AbbVieVenclexta | $326 | $107,90319 claims |
| Johnson & JohnsonXarelto, Procrit | $1,428 | $55,60857 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Tampa
- Eduardo SotomayorTampa$362K
- Kenneth ShainTampa$341K
- Ivan BorrelloTampa$336K
- Alberto ChiapporiTampa$325K
- Jingsong ZhangTampa$220K
- Sameh GaballaTampa$214K
- Adil DaudTampa$204K
- Jeffrey WeberTampa$193K
- Mayer FishmanTampa$193K
- Jonathan StrosbergTampa$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.